On February 3, Jabil Inc. announced that it entered into an agreement to acquire Pharmaceutics International, Inc. (Pii) for an undisclosed amount.
Pii is a contract development and manufacturing organization (CDMO) specializing in early stage, clinical, and commercial volume aseptic filling, lyophilization and oral solid dose manufacturing. Founded in 1994, Pii’s footprint has grown to more than 360,000 square feet across four sites on a single campus in Hunt Valley, Maryland.
Jabil Inc. is a global leader in engineering, manufacturing, and supply chain solutions. It is based in St. Petersburg, Florida and was founded in 1966.
By joining Jabil, Pii gains access to an expanded global infrastructure, cutting-edge automation, and enhanced supply chain efficiencies, enabling even greater responsiveness and innovation for its pharmaceutical partners.
According to data in the LevinPro HC database, this transaction represents the seventh CDMO acquisition of 2025. In 2024, there were 28 CDMO transactions, and 21 in 2023. This is also Jabil’s first acquisition of the year.
